- Research works
- 25 ▲ 125% vs 2013–17
- Citations
- 106 4.3 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 27% world 28%
Not ranked overall: Onxeo (France) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at Onxeo (France)?
By fractional works in all years, weighted toward what it does more of than the world: Homologous Recombination, Cancer Therapy, Cell Death, BRCA Mutation, PARP Inhibitors, Genomic Instability, Cancer and DNA Damage.
- Radiotherapy
- Gene Expression
- Genome Engineering
- Targeted Therapy
- Repair
- ATM and ATR Kinases
- Genomic Instability
- BRCA Mutation
- Cancer Therapy
- Homologous Recombination
- Cell Death
- PARP Inhibitors
- Cancer
- DNA Damage
- Chemotherapy
- Tumor Microenvironment
- RNA-Guided
- Nanoparticles
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 18 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 18 words, with their numbers
- Homologous Recombination8▲ 511×2 topics
- Cancer Therapy8▲ 54×8 topics
- Cell Death6▲ 124×3 topics
- BRCA Mutation6▲ 1417×1 topic
- PARP Inhibitors6▲ 1417×1 topic
- Genomic Instability4▲ 111×2 topics
- Cancer3▲ 9.9×5 topics
- ATM and ATR Kinases3▲ 207×1 topic
- DNA Damage3▲ 79×2 topics
- Repair3▲ 207×1 topic
- Chemotherapy2▲ 10×5 topics
- Targeted Therapy2▲ 28×4 topics
- Tumor Microenvironment2▲ 17×4 topics
- Genome Engineering1▲ 97×1 topic
- RNA-Guided1▲ 97×1 topic
- Gene Expression1▲ 7.9×4 topics
- Nanoparticles1▲ 3.6×7 topics
- Radiotherapy1▲ 11×2 topics
Which research topics does Onxeo (France) publish most on?
By volume in 2022–2025: PARP inhibition in cancer therapy, DNA Repair Mechanisms, CRISPR and Genetic Engineering and Soil Moisture and Remote Sensing.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 PARP inhibition in cancer therapy Oncology 2 works
- 2 DNA Repair Mechanisms Molecular Biology 1 works
- 3 CRISPR and Genetic Engineering Molecular Biology 0 works
- 4 Soil Moisture and Remote Sensing Environmental Engineering 0 works
- 5 Laser-Plasma Interactions and Diagnostics Nuclear and High Energy Physics 0 works
- 6 Laser-Matter Interactions and Applications Atomic and Molecular Physics, and Optics 0 works
- 7 Advanced Fiber Laser Technologies Atomic and Molecular Physics, and Optics 0 works
- 8 Cancer-related Molecular Pathways Oncology 0 works
- 9 Cancer Genomics and Diagnostics Cancer Research 0 works
- 10 Cancer therapeutics and mechanisms Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Onxeo (France)'s research output changed?
Output in 2018–2022 was 125% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Paris
- Centre National de la Recherche Scientifique
- Inserm
- Sorbonne Université
- Université Paris Cité
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives
- Université Paris 1 Panthéon-Sorbonne
- Institut Pasteur
- Assistance Publique – Hôpitaux de Paris
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.